<DOC>
	<DOCNO>NCT00858429</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray type radiation kill tumor cell . Specialized radiation therapy , yttrium Y 90 glass microspheres deliver high dose radiation directly tumor , may kill tumor cell cause less damage normal tissue . Drugs use chemotherapy , capecitabine , work different way stop growth tumor cell , either kill cell stop dividing . Capecitabine may also make tumor cell sensitive radiation therapy . PURPOSE : This phase I trial study side effect best dose yttrium Y 90 glass microspheres give together capecitabine treat patient liver cholangiocarcinoma liver metastasis .</brief_summary>
	<brief_title>Yttrium Y 90 Glass Microspheres Capecitabine Treating Patients With Liver Cholangiocarcinoma Liver Metastases</brief_title>
	<detailed_description>OBJECTIVES : - Establish maximally tolerate dose yttrium Y 90 glass microspheres combination capecitabine patient intrahepatic cholangiocarcinoma liver metastasis . - Characterize toxicity regimen patient . - Determine time tumor progression patient . OUTLINE : This dose escalation study yttrium Y 90 . Patients receive oral capecitabine twice daily day 1-14 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Patients also receive yttrium Y 90 glass microspheres intra-arterial hepatic infusion day 1-7 course 2 . After completion study therapy , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Doxifluridine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Intrahepatic cholangiocarcinoma Metastatic cancer confine liver Measurable disease , define ≥ 1 lesion accurately measure ≥ 1 dimension ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan Must tumor volume ≤ 50 % total liver volume base visual estimation PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,500/mm^3 Platelet count ≥ 75,000/mm^3 Serum creatinine ≤ 2.0 mg/dL Serum bilirubin ≤ 1.5 time upper limit normal Albumin ≥ 2.0 g/dL No baseline symptom laboratory value &gt; grade 2 severity NCI CTCAE v 3.0 criterion Not pregnant nursing Fertile patient must use effective contraception No malabsorption syndrome No severe liver dysfunction pulmonary insufficiency No complete occlusion main portal vein No contraindication iodinebased contrast agent No contraindication hepatic artery catheterization ( e.g. , vascular abnormality bleed diathesis ) No prior unanticipated severe reaction fluoropyrimidine therapy , know hypersensitivity fluorouracil , know dihydropyrimidine dehydrogenase deficiency PRIOR CONCURRENT THERAPY : No prior radiotherapy liver No 2 prior therapy metastatic disease liver No prior intervention compromise Ampulla Vater At least 4 week since prior concurrent sorivudine brivudine No concurrent cimetidine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>adult primary cholangiocellular carcinoma</keyword>
</DOC>